retatrutide trials ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide for the treatment of
Description
2023 Oct 19
In total, 63 biopsy slide sections were produced and analyzed
Chilibeck, P
Without those intermediate checks, a positive functional result could still be metabolic, vascular, rehabilitation-related, or selection-driven rather than direct neuroprotection
